Cardiac amyloidosis: A case report
DOI:
https://doi.org/10.24265/horizmed.2018.v18n4.12Keywords:
Amyloidosis, Cardiomyopathies, Heart failure, Restrictive cardiomyopathyAbstract
Cardiac amyloidosis is a rare clinical entity and, therefore, almost unknown. It shows as a restrictive cardiomyopathy, since it is an infiltrative disease caused by the extracellular deposition of amyloids in the cardiac wall. Although it may be systemic, the heart condition determines its poor prognosis. This is the case of a 38-year-old patient who was admitted for dyspnea and severe fatigue. He was diagnosed with IgA multiple myeloma, lambda light chains, clinical stage IIIB, and initiated treatment with cyclophosphamide, thalidomide and dexamethasone. The patient stopped the treatment, and returned after one year and 2 months with an advanced disease and presence of amyloidosis. The patient progressed torpidly and eventually died. A review of the medical literature is performed concerning amyloidosis types, physiopathology, diagnostic methods and treatment.
Downloads
References
Quock TP, Yan T, Chang E, Guthrie S, Broder MS. Epidemiology of AL amyloidosis: a real-world study using US claims data. Blood Adv. 2018;2(10):1046-1053.
Cibeira T, Bladé J. Amiloidosis primaria: diagnóstico, pronóstico y tratamiento. Hematológica. 2011; 96 (1):13-18.
García-Pavía P, Tomé-Esteban M, Rapezzi C Amiloidosis. También una enfermedad del corazón. Rev Esp Cardiol. 2011;64:797-808.
Bhogal S, Ladia V, Sitwala P, Cook E, Bajaj K, Ramu V, Lavie CJ, Paul TK. Cardiac Amyloidosis: An Updated Review With Emphasis on Diagnosis and Future Directions. Curr Probl Cardiol. 2018;43(1):10-34.
Ruberg FL, Berk JL. Tranthyrerin cardiac amyloidosis. Circulation. 2012; 126 (10): 1286-1300.
Harrison C, Harrison D. Amiloidosis senil. Acta Med Grupo Angeles. 2018;16(1):58-62.
Fikrle M, Palecek T, Kuchynka P, Nemecek E, Bauerova L, Straub J, Rysava R. Cardiac amyloidosis: A comprehensive review. Cor et Vasa. 2013:55;E60-E75.
Rodríguez MA, Méndez MA. El Proteosoma, sus Inhibidores y Toxicidad Cardíaca. Rev Clín Esc Med. 2018;8(2):11-21.
Navarro-Ulloa OD, Conde-Cardona G, Gamero-Tafur JA, Ibarra-Jiménez G. Miocardiopatía restrictiva por amiloidosis. Rev Colomb Cardiol. 2016;23(6):525.e1---525.e5
Gertz M. Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018. Blood Cancer J. 2018;8(5):44.
Falk RH, Alexander KM, Liao R, Dorbala S. AL (Light-Chain) cardiac amyloidosis: a review of diagnosis and therapy. J Am Coll Cardiol. 2016;68 (12):1323–41.
Siddiqi OK, Ruberg FL. Cardiac amyloidosis: An update on pathophysiology, diagnosis and treatment. Trends Cardiovasc Med. 2018;28(1):10-21.
Duque M, Velásquez J, Marín J, Aristizábal J, Astudillo V, Medina L. Amiloidosis cardiaca. Rev Colomb Cardiol. 2009;16:118-127.
Núñez LE, Chacón S. Amiloidosis cardiaca: presentación de un caso y revisión de la literatuta. Rev Comb Cardiol. 2012;19(1):37-41.
Cyrille NB, Goldsmith J, Alvarez J, Maurer MS. Prevalence and prognostic significance of low QRS voltage among the three main types of cardiac amyloidosis. Am J Cardiol 2014;114:1089–93.
Sayago-Silva I. Amiloidosis AL Cardiaca Avanzada: Análisis de estrategias diagnósticas y Terapéuticas. [master's thesis] Madrid: Universidad Autónoma de Madrid; 2017. 128p.
Bhatti S, Watts E, Syed F, Vallurupalli S, Pandey T, Jambekar K, et al. Clinical and prognostic utility of cardiovascular magnetic resonance imaging in myeloma patients with suspected cardiac amyloidosis. Eur Heart J Cardiovasc Imaging, 2016;17:970-977.
Donnelly J, Hanna M. Cardiac amyloidosis: An update on diagnosis and treatment. Cleve Clin J Med. 2017;84(3):12-26.
Cortes M, Battioni L, Sciancalepore A, Costabel J. Amiloidosis cardiaca simulando una miocardiopatía hipertrófica. Rev Fed Arg Cardiol. 2015;44(4):229-232.
Merlini G, Lousada I, Ando Y, et al. Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis. Leukemia. 2016;30(10):1979-1986.
Shameem Mahmood S, Palladini G, Sanchorawala V, Wechalekar A. Update on treatment of light chain amyloidosis. Haematologica. 2014; 99 (2):209-221.
Published
How to Cite
Issue
Section
License
Copyright (c) 2018 Horizonte Médico (Lima)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Horizonte Médico (Lima) (Horiz. Med.) journal’s research outputs are published free of charge and are freely available to download under the open access model, aimed at disseminating works and experiences developed in biomedical and public health areas, both nationally and internationally, and promoting research in the different fields of human medicine. All manuscripts accepted and published in the journal are distributed free of charge under the terms of a Creative Commons license – Attribution 4.0 International (CC BY 4.0).
